NCT03042299View on ClinicalTrials.gov

A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 10, 2017

Primary Completion Date

March 11, 2017

Study Completion Date

March 11, 2017

Conditions
Japanese Healthy Adult Male Participants
Interventions
DRUG

TAK-536

TAK-536 granules.

DRUG

TAK-536

TAK-536 tablet.

Trial Locations (1)

Unknown

Nishi Kumamoto Hospital, Kumamoto

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY